Strand was started by biological engineers working together at MIT. Building on the idea of creating smart therapies that are capable of making sophisticated decisions, they sought to apply the concept of the emerging field of mRNA therapeutics. This area was untapped by traditional synthetic biology, which led them to build their own mRNA “programming language,” creating the world’s first platform for mRNA smart therapies.
Strand’s mRNA programming technology promises to make mRNA therapies safer and more effective by programming the location, timing, and intensity of therapeutic protein expression inside a patient’s body using mRNA-encoded logic circuits. These circuits can implement cell-type specific expression by sensing and classifying the unique miRNA expression signatures of cells, as well as controlling the dosage of protein expression by responding to exogenously administered small molecules.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
2017
Founded
Investors
0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
When was Strand Therapeutics founded?
Strand Therapeutics was founded in 2017.
What industry is Strand Therapeutics in?
Strand Therapeutics operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Strand Therapeutics based?
Strand Therapeutics is headquartered in Cambridge, United States.
Find investors for your startup like Strand Therapeutics
Gritt sends AI-personalised outreach to each investor — from your Gmail